Skip to main content

Table 3 Differences in mean intraocular pressure with each treatment

From: Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study

Per-protocol population

Treatment group/time-point (baseline)

Baseline-month 3

Treatment group/time-point (crossover)

Month 3-month 6

 

mm Hg ± SD

Pvalue*

n

 

mm Hg ± SD

Pvalue*

n

Bim/tim 8 am

-4.9 ± 1.7

0.0073

30

Dorz/brim/tim 8 am

+3.0 ± 0.4

0.0006

30

Bim/tim 10 am

-4.7 ± 0.2

0.0045

Dorz/brim/tim 10 am

+0.2 ± 0.3

0.2710

Dorz/brim/tim 8 am

-3.3 ± 1.2

<0.0001

26

Bim/tim 8 am

-0.9 ± 0.8

0.0770

26

Dorz/brim/tim 10 am

-3.0 ± 1.0

<0.0001

Bim/tim 10 am

0.0 ± 0.6

0.9463

Intent-to-treat population

Treatment group/time-point (baseline)

Baseline-month 3

Treatment group/time-point (crossover)

Month 3-month 6

 

mm Hg ± SD

P value*

n

 

mm Hg ± SD

P value*

n

Bim/tim 8 am

-4.7 ± 1.3

<0.0001

41 (BL)–35 (M3)

Dorz/brim/tim 8 am

+2.9 ± 2.9

0.0006

35 (M3)–26 (M6)

Bim/tim 10 am

-4.4 ± 0.4

<0.0001

Dorz/brim/tim 10 am

+0.3 ± 0.3

0.5940

Dorz/brim/tim 8 am

-3.1 ± 1.3

<0.0001

37 (BL)–28 (M3)

Bim/tim 8 am

-0.1 ± 0.8

0.9286

28 (M3)–32 (M6)

Dorz/brim/tim 10 am

-3.0 ± 0.0

<0.0001

Bim/tim 10 am

0.0 ± 0.6

0.9463

  1. *Student t test.
  2. Bim/tim, bimatoprost 0.03% and timolol maleate 0.5%; BL, baseline; dorz/brim/tim, dorzolamide 2%, brimonidine 0.2%, and timolol maleate 0.5%; M3, month 3; M6, month 6; SD, standard deviation.